Articles from Larkspur Biosciences, Inc.

First-in-human, Phase 1 Study of LRK-4189 to Begin in the Fourth Quarter

WATERTOWN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a company pioneering a new wave in cancer therapy by targeting cancer-intrinsic drivers of immune evasion, announced that it will present positive preclinical efficacy data for LRK-A, Larkspur’s novel, lead investigational therapy targeting the lipid kinase PIP4K2C, in primary human tumor samples and an in vivo model of colorectal cancer (CRC). The data will be featured in a poster presentation at the 115th Annual Meeting of the American Association for Cancer Research (AACR 2024) in San Diego, CA.

WATERTOWN, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a company pioneering a new wave in cancer therapy that stops immune evasion from where it starts in the tumor, announced that its Chief Executive Officer, Catherine Sabatos-Peyton, PhD, will participate in the following upcoming biotech events, including two events surrounding the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco:

-- Research emphasizes the significant role of Pin1 in influencing critical cancer mechanisms to drive a pro-immune response, reinforcing Pin1 as a promising target for therapeutic interventions

Research foundational to Larkspur’s newly disclosed TIM-1 program published by founder Vijay K. Kuchroo in Nature

WATERTOWN, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a biotechnology company building the next precision immunotherapies to outsmart cancer, announced that they will be participating in the 2023 BIO International Convention being held June 5-8 at the Boston Convention & Exhibit Center, Boston, MA.

Addressing the Key Bottlenecks in the Tumor Microenvironment That Allow a Tumor to Subvert the Immune System